Novel Biomarkers of Cancer Treatment Response and Resistance

The increasing accessibility of sequencing has allowed physicians to use DNA alterations as biomarkers to identify patients who benefit from specific cancer treatments. However, the majority of patients do not currently have actionable alterations. There is a clear need to identify new biomarkers which can utilize the wealth of data generated from sequencing techniques to help clinicians match patients with the most beneficial therapies. To address this, the project team will undertake a unique collaboration with a biotechnology company. Dr. Zhao is uniquely suited for this collaboration, given his extensive track record of clinical biomarker development and history of successful collaborations with industry. This partnership is expected to yield additional grants, clinical trials and intellectual property to improve outcomes for cancer patients.

PRINCIPAL INVESTIGATOR:
Shuang Zhao, assistant professor of human oncology

INDUSTRY PARTNER: